Shire PLC (SHPG) Upgraded to Buy by Liberum Capital

Liberum Capital upgraded shares of Shire PLC (NASDAQ:SHPG) from a hold rating to a buy rating in a research report released on Tuesday morning.

SHPG has been the topic of several other research reports. BidaskClub downgraded Shire PLC from a sell rating to a strong sell rating in a report on Wednesday, July 19th. Barclays PLC downgraded Shire PLC from an overweight rating to an equal weight rating in a report on Friday, August 11th. Evercore ISI assumed coverage on Shire PLC in a report on Wednesday, August 16th. They issued an outperform rating and a $196.00 price objective on the stock. Royal Bank Of Canada reiterated a buy rating and issued a $213.00 price objective on shares of Shire PLC in a report on Monday, October 2nd. Finally, Piper Jaffray Companies set a $159.00 price objective on Shire PLC and gave the stock a hold rating in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The company has an average rating of Buy and an average target price of $212.18.

Shire PLC (NASDAQ:SHPG) opened at $147.37 on Tuesday. The company has a market capitalization of $43,610.00, a PE ratio of 9.58, a PEG ratio of 0.77 and a beta of 1.60. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. Shire PLC has a twelve month low of $137.17 and a twelve month high of $192.15.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.17 EPS. research analysts expect that Shire PLC will post 15 EPS for the current year.

WARNING: This piece of content was originally published by BBNS and is the property of of BBNS. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/shire-plc-shpg-upgraded-to-buy-by-liberum-capital/1783075.html.

A number of institutional investors have recently bought and sold shares of the business. Inspirion Wealth Advisors LLC boosted its position in Shire PLC by 0.4% during the 2nd quarter. Inspirion Wealth Advisors LLC now owns 1,944 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 8 shares in the last quarter. Synovus Financial Corp boosted its position in Shire PLC by 0.4% during the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 11 shares in the last quarter. Baldwin Investment Management LLC boosted its position in Shire PLC by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 23 shares in the last quarter. Hartford Financial Management Inc. boosted its position in shares of Shire PLC by 5.4% in the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 32 shares in the last quarter. Finally, Lumbard & Kellner LLC boosted its position in shares of Shire PLC by 0.3% in the 2nd quarter. Lumbard & Kellner LLC now owns 18,170 shares of the biopharmaceutical company’s stock worth $3,003,000 after purchasing an additional 55 shares in the last quarter. 18.27% of the stock is currently owned by institutional investors and hedge funds.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.

 


Latest News

MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity


Leave a Reply

 
© 2006-2017 BBNS.